Meta-Analysis of MiR-122 in Predicting Cardiovascular and Cerebrovascular Diseases

Abstract Objective To evaluate the diagnostic value of MiR-122 in predicting cardiovascular and cerebrovascular diseases systematically. Methods Searching China National Knowledge Infrastructure(CNKI), Wanfang Database, VIP Database (VIP), China Biomedical Literature Database (CBM), Clinical Registry, PubMed, Cochrane Library and Embase Library to obtain relevant documents. The time frame is from January 1, 2006 to February 28, 2021. MiR-122 plays a diagnostic role in patients of cardiovascular and cerebrovascular diseases with randomized controlled trials and cross-sectional studies. According to the inclusion and exclusion criteria, the literatures were screened, data extracted and related quality evaluated. Cochrane System Reviewer Manual Version 5.0 was applicable to related quality evaluation and Review Manager 5.3 was used for meta-analysis. Results A total of 23 articles were included and 6375 patients altogether. The meta-analysis showed that compared with the control group, MiR-122 was more effective in the patients of myocardial infarction (WMD= -2.33, 95%CI [-2.88,-1.78], P<0.0001), Angina pectoris and cardiovascular disease (WMD= -0.45, 95%CI [-0.61,-0.29], P<0.00001). Cerebrovascular diseases also have higher expression levels of MiR-122(WMD=- 0.34, 95% CI [-0.53, 0.33], P<0.00001). The prognosis of patients with high MiR-122 expression are worse (WMD=-2.20, 95%CI[-2.66,-1.75], P<0.00001). There are differences between the groups, with statistical significance (P<0.05). Conclusion MiR-122 has great diagnostic value in predicting cardiovascular and cerebrovascular diseases, and expression is elevated in diseases such as myocardial infarction, angina pectoris and stroke. Thus it has diagnostic value in the prognosis of patients with cardiovascular and cerebrovascular diseases.